Fax: (301) 402-0817
Article first published online: 19 OCT 2010
Copyright © 2010 American Cancer Society
Volume 116, Issue 23, pages 5344–5347, 1 December 2010
How to Cite
Shiels, M. S., Goedert, J. J. and Engels, E. A. (2010), Recent trends and future directions in human immunodeficiency virus-associated cancer. Cancer, 116: 5344–5347. doi: 10.1002/cncr.25705
See original referenced article on pages 5507–16, this issue.
This article is a US Government work and, as such, is in the public domain in the United States of America.
- Issue published online: 23 NOV 2010
- Article first published online: 19 OCT 2010
- Manuscript Accepted: 7 SEP 2010
- Manuscript Revised: 31 AUG 2010
- Manuscript Received: 19 JUL 2010
Malignancies, including the 3 that are part of the definition of acquired immunodeficiency syndrome (AIDS) (Kaposi sarcoma [KS], non-Hodgkin lymphoma [NHL], and cervical cancer) as well as certain non-AIDS–defining cancers, cause significant morbidity and an estimated one-third of the deaths reported among patients infected with the human immunodeficiency virus (HIV).1 Seaberg et al2 examined cancer incidence among HIV-infected and HIV-uninfected men who have sex with men (MSM) in the US Multicenter AIDS Cohort Study (MACS). The cancer risk in HIV-infected men was compared internally with that of HIV-uninfected MACS participants and externally with general population cancer data from the Surveillance, Epidemiology, and End Results (SEER) registry program.
The MACS analysis highlighted several interesting and important trends in AIDS-defining and non-AIDS–defining cancers among HIV-infected individuals. The authors reported that the incidence rates of KS and NHL, which fell substantially with the widespread use of highly active antiretroviral therapy (HAART) beginning in 1996, continued to decline through 2007, presumably because of improvements in HAART. These results are consistent with most3, 4 but not all5 previous reports. It is interesting to note that, KS and NHL rates began to decline even before the introduction of HAART,5 which perhaps may be attributable to single-agent and dual-agent antiretroviral therapies that were in use before 1996.5
Although comparing cancer rates by calendar period is useful for gauging the overall population effectiveness of changes in antiretroviral therapy, a strength of cohorts such as that used in the MACS is that they also have data regarding actual medication use and HIV disease markers. Even within the HAART era, not all HIV-infected individuals are receiving HAART, medication regimens vary, and the effectiveness of HAART in suppressing HIV replication and restoring immune function may be incomplete. Analyses that consider only calendar periods cannot determine whether the decline in risk over time is driven by a larger percentage of individuals receiving therapy or improvements in HAART regimens. Additional studies that examine how the risk of KS and NHL varies with actual HAART use, specific medications, and HAART effectiveness as assessed by HIV disease markers would help to clarify why the risk of KS and NHL was found to remain elevated in the most recent HAART calendar period. Is the continuing risk because of people not taking HAART, poor adherence with medications, ineffectiveness of HAART because of the emergence of resistant HIV, or incomplete immune reconstitution even in people being treated with virologically suppressive regimens? Data from France indicate that CD4 cell counts and plasma HIV RNA levels continue to be important predictors of KS and NHL risk for people receiving HAART.6 We recognize that a challenging issue in evaluating the effect of HAART on cancer risk is confounding by indication, that is that the sickest people are prescribed HAART, which can lead to an artifactual positive association between HAART use and adverse health outcomes. Nonetheless, this methodological issue has been addressed in recent analyses of observational data from HIV cohorts.7
In contrast to the declining trends for KS and NHL noted among HIV-infected MACS participants, Seaberg et al reported a concerning rise in anal cancer incidence over time, including a suggestive increase within the HAART era itself. This finding is in keeping with results from most previous studies, which have observed a stable or increasing risk of anal cancer in the HAART era or with HAART use.8-10 HIV-infected individuals, including women and heterosexual men as well as MSM,11 are at an increased risk of anal cancer and other human papillomavirus (HPV)-related cancers.3, 8 Prolonged HIV-induced immunosuppression, as indicated by an extended time spent with a low CD4 cell count, is a risk factor for anal cancer.6 However, because the restoration of the immune system by HAART does not appear to reduce the risk of the immediate precursors of anal cancer,12 it has been postulated that immune suppression may only impact the persistence of HPV infection and not subsequent progress to invasive malignancy.10, 12, 13 Because the latency period for persistent HPV infection resulting in anal cancer may be quite long, even decades, if the initiation of HAART is delayed, therapy may be given to patients too late to stop the development of anal cancer, and may indirectly facilitate carcinogenesis by prolonging survival. One possibility is that earlier HAART initiation (ie, initiation at higher CD4 cell counts) would allow for HPV clearance before the development of early precancerous lesions.
Lung cancer risk appeared higher in HIV-infected MACS participants compared with participants not infected with HIV, although this difference was not found to be statistically significant. Registry linkage studies and studies comparing with external rates have consistently found that HIV-infected individuals had 2-fold to 3-fold higher lung cancer rates compared with the general population.5, 9, 14 These associations are partially driven by the high proportion of HIV-infected individuals who smoke cigarettes compared with the general population. In fact, lung cancer among HIV-infected individuals occurs almost exclusively among smokers. Nonetheless, studies have found an increased risk of lung cancer with HIV, even after directly or indirectly adjusting for differences in smoking prevalence.15, 16 To the best of our knowledge, the mechanism by which HIV infection increases lung cancer risk remains unclear, although several hypotheses have been proposed. HIV-infected individuals experience increased pulmonary inflammation, repeated and chronic pulmonary infections, and deficiencies in antioxidants and other nutrients, all of which may act together with tobacco use to increase lung cancer risk.17 Along these lines, our recent analyses of US registry linkage data indicated that people with AIDS who have had repeated episodes of bacterial pneumonia are at a somewhat increased risk of developing lung cancer.18
A major strength of the study by Seaberg et al is the internal comparison of cancer risk within the MACS. Many prior studies reporting on excess cancer risk in HIV-infected individuals have relied on comparisons between cohort data and general population cancer rates9 or matches between HIV/AIDS and cancer registries.4, 5, 14 HIV-uninfected individuals enrolled in the same cohort study and drawn from the same source population are a more appropriate comparison group than the general population, because they are more similar to HIV-infected individuals with regard to their demographic, socioeconomic, and behavioral characteristics. Furthermore, studies that include individual-level data on all cohort participants, such as the MACS, allow for careful control of any residual differences in these characteristics. For example, Seaberg et al were able to restrict the analysis to smokers and adjust for level of cigarette smoking in their lung cancer analysis, whereas data regarding smoking are not available in population-based registries.
Assessing the associations between HIV infection and cancer risk within a cohort study is not without weaknesses. Registry-based studies can include more than 100 times the number of HIV-infected individuals that are included in cohort studies such as the MACS, enabling the detection of much smaller differences in cancer risk between HIV-infected and HIV-uninfected populations. In the MACS analysis, many of the comparisons between HIV-infected and HIV-uninfected individuals were likely underpowered, and therefore, some associations with HIV infection may have been missed. In addition, the MACS study included only 1 HIV risk group (MSM) and lacked data regarding cancer risk in women. Future consortia that combine data from US and international cohorts, include both HIV-infected and comparable HIV-uninfected individuals, and include people from diverse demographic groups would be ideal for studying HIV infection and cancer risk, bridging the gap between registry-based studies (with robust statistical power and population representativeness) and HIV cohort studies (with detailed individual-level data).
An additional point to note in the current MACS analysis is that HIV-uninfected men were observed to have 47% fewer cancers than expected based on SEER general population rates (standardized incidence ratio [SIR], 0.53; 95% confidence interval [95% CI], 0.43-0.66). Although Seaberg et al postulated that MACS participants may have been at a generally low risk for most cancers, this apparently low risk could plausibly reflect underascertainment of cancers. Cancers in the MACS were, according to the authors, ascertained through interviews; abstraction and review of medical records; reports by the patient or their next of kin; and review of vital status records, including data from the National Death Index.2 Cancers not reported by participants or occurring after loss to follow-up would not have been detected by study personnel, potentially leading to artificially low cancer rates.
Two examples in which underascertainment appears possible are lung and anal cancers. Because cigarette smoking prevalence was found to be far greater in HIV-uninfected MACS participants (40% of whom were current smokers) than in the US general population (24% current smokers in 2000),19 an elevated lung cancer risk would be expected. However, the risk of lung cancer appeared reduced among HIV-uninfected men in the MACS (SIR, 0.30; 95% CI, 0.11-0.66). Furthermore, male homosexuality and receptive anal intercourse are strong, established risk factors for anal cancer,20 but HIV-uninfected MSM in the current MACS analysis manifested only a modest and nonsignificant elevation compared with men in the general population (SIR, 2.50; 95% CI, 0.30-9.03). Thus, we believe that the results for lung and anal cancers likely reflect some degree of underascertainment of these cancers and, by implication, perhaps other cancers as well. If present, the underascertainment of cancers is likely nondifferential by HIV status, and thus would attenuate internal comparisons between HIV-infected and HIV-uninfected men. This issue emphasizes the importance of complete and accurate cancer ascertainment in HIV cohort studies. One approach would be to supplement the ongoing data collection activities by linking the data from cohort participants with population-based cancer registries.
Among HIV-infected individuals, HAART has improved immune function; reduced the risk of AIDS, including AIDS-defining malignancies; and dramatically prolonged survival. As a result, HIV-infected individuals are living to older ages at which the risk of non-AIDS–defining cancers steeply increases. Thus, in the coming years, even if the number of AIDS-defining malignancies continues to decline, the number of non-AIDS–defining cancers diagnosed in HIV-infected individuals will increase. The importance of prevention, early detection, and treatment efforts targeted toward HIV-infected individuals has also grown. Because lung cancer is the most frequent non-AIDS–defining malignancy, smoking cessation efforts are essential to reduce morbidity and mortality. Furthermore, HIV-infected women should adhere to specific Papanicolaou (Pap) testing guidelines tailored toward woman with HIV infection to prevent cervical cancer. In addition, future research is needed to determine the efficacy of anal cancer screening with the Pap test in HIV-infected MSM as well as other risk groups. Given the ever improving life expectancy afforded by effective HAART, age-specific screening recommendations for colon, prostate, and breast cancers should be applied to HIV-infected individuals as they are for the general population.
The success of HAART at prolonging survival now brings new challenges as HIV-infected individuals age. It is important that we continue to build on the findings of Seaberg et al2 and others by working toward a better understanding of the etiology of cancer in the setting of HIV infection. We must also devote continuing effort and attention to cancer prevention with the goal of reducing cancer incidence, morbidity, and mortality among HIV-infected individuals.
CONFLICT OF INTEREST DISCLOSURES
Supported by the Intramural Research Program of the National Cancer Institute.
- 19Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System Annual Survey Data 1984-2008. Available at: http://apps.nccd.cdc.gov/brfss/sex.asp?cat=TU&yr=2000&qkey=4396&state=US. Accessed on October 20, 2009.